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Background. Oral azithromycin given to women in labor decreases maternal and neonatal bacterial carriage but increases azi-
thromycin-resistant bacteria during at least 4 weeks following the intervention. We assessed the prevalence of bacterial carriage and 
azithromycin resistance 12 months after treatment among study infants.
Methods. Nasopharyngeal swabs (NPSs) were collected between November 2014 and May 2015 from children aged 11–13 months 
whose mothers had received azithromycin or placebo during labor. Streptococcus pneumoniae and Staphylococcus aureus were iso-
lated using conventional microbiological methods. Antibiotic susceptibility was determined by disk diffusion and confirmed by Etest 
or VITEK-2.
Results. NPSs were collected from 461 children. The prevalence of S.  pneumoniae and S.  aureus was similar between chil-
dren from the azithromycin and placebo arms (85.0% vs 82.1%; odds ratio [OR], 1.23 [95% confidence interval {CI}, .73–2.08] for 
S. pneumoniae and 21.7% vs 21.3%; OR, 1.02 [95% CI, .64–1.64] for S. aureus). Prevalence of azithromycin-resistant S. pneumo-
niae was similar in both arms (1.8% vs 0.9% in children from the azithromycin and placebo arms, respectively; OR, 2.10 [95% CI, 
.30–23.38]); resistance to other antibiotics was also similar between arms. For S. aureus, there was no difference in azithromycin 
resistance between children in the azithromycin (3.1%) and placebo (2.6%) arms (OR, 1.22 [95% CI, .35–4.47]) or resistance to any 
other antibiotics.
Conclusions. The higher prevalence of S.  aureus azithromycin resistance observed among women treated during labor and 
their babies 4 weeks after treatment had waned 12 months after delivery. Azithromycin intervention did not induce other antibiotic 
resistance to S. pneumoniae or S. aureus.
Clinical Trials Registration. NCT01800942.
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Azithromycin is a second-generation broad-spectrum mac-
rolide used to treat infections such as pneumonia, middle 
ear infections, and sexually transmitted infections [1, 2]. 
Azithromycin has also been used in mass drug administra-
tion (MDA) campaigns to control trachoma in several endemic 
countries in Africa [3–6]. The impact of these MDA campaigns 
has varied from one country to another [6–8], but when the 
baseline prevalence of trachoma is low, 1 round of MDA with 
azithromycin (MDA-Z) is sufficient to eliminate trachoma [3]. 
Furthermore, MDA-Z may have beneficial effects beyond tra-
choma control. In rural Gambia, 3 annual rounds of MDA-Z 
reduced by 24.2% asymptomatic pneumococcal carriage for at 
least 1 month [9] and, in Ethiopia, it reduced by 49% all-cause 
mortality in children aged 1–9 years [10].
Azithromycin has also been given in combination with sul-
fadoxine-pyrimethamine (SP) during pregnancy with the aim 
of reducing the prevalence of low birth weight. In Malawi and 
Papua New Guinea, babies born to mothers who received azith-
romycin and SP had a reduced risk of low birth weight [11, 12].
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MDA-Z may increase the prevalence of macrolide resistance, 
even after the administration of a single dose. In The Gambia, 
MDA-Z resulted in a short-term increase in azithromycin-re-
sistant Streptococcus pneumoniae [9], while in Tanzania a 
single dose of MDA-Z increased prevalence of resistance for 
>6  months [13]. The prevalence was also high in Ethiopia 
among children after receipt of several annual doses [14] and 
declined after azithromycin was discontinued [15].
For Staphylococcus aureus, another common bacterial patho-
gen, there are increasing data on the effect of MDA-Z on resis-
tance. In rural Gambia [3], 3 annual rounds of MDA-Z were 
associated with a long-term (30  months after the first round 
MDA-Z) increase in both the prevalence of azithromycin-resis-
tant and inducible macrolide lincosamides and streptogramin 
B (MLSB)–resistant S. aureus [16]. In Papua New Guinea, the 
proportion of azithromycin-resistant S.  aureus was 5 times 
higher among pregnant women treated with azithromycin than 
in those in the control group [17].
In a recent trial in The Gambia, administering 2  g of oral 
azithromycin during labor reduced significantly maternal and 
neonatal nasopharyngeal carriage of S. pneumoniae, S. aureus, 
and group B Streptococcus [6], as well as maternal and neona-
tal infections [18, 19]. Four weeks after birth, children in the 
intervention arm had similar prevalence of nasopharyngeal 
carriage of S. pneumoniae azithromycin resistance compared to 
those in the control arm (2.1% vs 2.2%; P = 1.000), but higher 
prevalence of S. aureus azithromycin resistance (4.5% vs 16.7%; 
P  <  .001) [20]. To determine the persistence of azithromycin 
resistance among study children, we collected nasopharyngeal 
swabs (NPSs) at their first birthday.
MATERIALS AND METHODS
Study Site and Population
Trial participants were recruited from the Bundung Maternal 
and Child Health Hospital, formerly called Jammeh Foundation 
for Peace, a government-run health center located in western 
Gambia that manages on average 4500 deliveries per year [21]. 
The population covers the main ethnic groups in The Gambia 
with a high illiteracy rate. The climate of the area is typical of 
the sub-Sahel region.
Main Trial
Details of the study protocol have been described elsewhere 
[21]. In brief, this was a phase 3, double-blind, placebo-con-
trolled trial where 829 pregnant women attending the labor 
ward in the study health facility were randomized to receive a 
single oral dose of 2 g of either oral azithromycin or placebo 
(ratio 1:1). The trial started in April 2013 and lasted 14 months 
(12-month recruitment period and 2 additional months of 
follow-up). Study participants (women and their newborns) 
were monitored for 8 weeks after the intervention. Neonatal 
NPSs were collected during the first 4 weeks of the follow-up 
as part of the trial. Prevalence of nasopharyngeal carriage of 
S.  pneumoniae was significantly lower during the entire neo-
natal period among neonates exposed to azithromycin (at day 
28: 37.2% vs 24.8%; prevalence ratio [PR],  0.67 [95% confi-
dence interval {CI}, .53–.83]; P < .001). Prevalence of carriage 
of S. pneumoniae–resistant strains was low throughout and sim-
ilar between arms (at day 28: 2.1% vs 2.2%; PR, 1.04 [95% CI, 
.40–2.75]; P = 1.000). For S. aureus, prevalence of nasopharyn-
geal carriage peaked at day 6 and by day 28 was still significantly 
lower in the azithromycin arm (35.3% vs 25.6%; PR, 0.73 [95% 
CI, .58–.91]; P = .005), whereas prevalence of azithromycin-re-
sistant S. aureus carriage peaked at day 28 (4.5% vs 16.7% in the 
azithromycin and placebo arms; PR, 3.68 [95% CI, 2.19–2.75]; 
P < .001) [20].
Cross-sectional Survey
Between November 2014 and May 2015, children aged 
12  months (range, 11–13  months) whose mother had partic-
ipated in the main trial were visited at home and had an NPS 
collected. Consent was obtained by a trained nurse blinded to 
the treatment allocation.
Ethical Approval
Both the main trial and the cross-sectional survey (CSS) were 
approved by the Joint Medical Research Council/The Gambia 
Government Ethics Committee. Mothers of children included 
in the CSS signed an additional informed consent.
Sample Handling
The NPS was collected using calcium alginate (Expotech 
USA) swab as described previously [21]. In brief, each swab 
was immediately placed into a vial containing skim milk-tryp-
tone-glucose-glycerol transport medium and then into a cold 
box before being transported to the laboratory within 8 hours 
[22]. Upon receipt, the tubes were vortexed for a minimum of 
20 seconds before being stored in freezers at –70°C.
Laboratory Methods
Details of the laboratory methods were described previously 
[21]. In brief, 50 μL of the sample was dispensed onto genta-
micin blood agar (GBA) (CM0331 Oxoid, United Kingdom, 
plus 5% sheep blood) and mannitol salt agar (MSA) (CM0085 
Oxoid, United Kingdom) for selective isolation of S. pneumo-
niae and S. aureus, respectively.
Streptococcus pneumoniae
After 20–24 hours of incubation at 37°C with 5% carbon diox-
ide, GBA plates were examined for typical α-hemolytic col-
onies. Morphologically distinct α-hemolytic colonies were 
selected and subcultured on another blood agar to obtain 
pure growth and screened for optochin susceptibility [22]. 
Streptococcus pneumoniae isolates were confirmed as described 
previously [21].
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Staphylococcus aureus
Following 48 hours of incubation at 37°C, MSA plates were exam-
ined for typical staphylococci colonies. Pale to golden yellow 
dome-shaped colonies 1–2 mm in diameter were cultured onto 
blood agar to obtain pure growth. A coagulase test was performed 
on all suspected colonies using the Staphaurex plus kit (Oxoid, 
United Kingdom, catalog number OXR30950201). Isolates testing 
positive for coagulase were confirmed to be S. aureus.
Antibiotic Susceptibility Testing
Antibiotic susceptibility was performed as described previously 
[21]. In brief, resistance was initially screened by disk diffusion 
method. Both S. pneumoniae and S. aureus isolates were screened 
using the following antibiotic discs: azithromycin (15 μg), chlo-
ramphenicol (30  μg), clindamycin (2  μg), and erythromycin 
(15 μg). In addition, only S. pneumoniae isolates were screened 
for trimethoprim-sulfamethoxazole (1.25/23.75  μg) and oxa-
cillin (1 μg), and S. aureus isolates were screened for cefoxitin 
(30 μg). All isolates that were of intermediate or resistant by the 
disk diffusion method were further tested using the Etest for 
confirmation except those isolates resistant to cotrimoxazole. 
Due to limited resources, only 90 of these isolates were ran-
domly selected to be confirmed by the Etest. Susceptibility to 
the different antibiotics was determined following the Clinical 
and Laboratory Standards Institute guidelines [23]. In addition, 
D-test was performed on all macrolide (azithromycin and/
or erythromycin)–resistant clindamycin-sensitive isolates to 
assess inducible clindamycin resistance [24]. In an additional 
effort to confirm resistance, all S. pneumoniae isolates found to 
be resistant by Etest to azithromycin, erythromycin, or clinda-
mycin were retested using the VITEK-2 (bioMérieux, France). 
The VITEK-2 results were considered definitive.
Data Management and Statistical Analysis
Laboratory data were transcribed onto bar-coded forms and 
submitted to data management for entry. The data were double 
entered in OpenClinica (www.openclinica.com), and antibiotic 
susceptibility data for S. pneumoniae were stored in a REDcap 
database.
For each antibiotic, the resistant bacterial carriage preva-
lence was compared between trial arms using the χ2 test. This 
was done for both S. pneumoniae and S. aureus. In addition, we 
assessed if resistance up to day 28 posttreatment was associated 
with resistance 12 months later. For this analysis, only children 
who were sampled during all 5 time points in the trial (days 0, 
3, 6, 14, and 28) and were also sampled in the 12-month CSS 
were included. All analyses were carried out using Stata version 
12.0 software.
RESULTS
Study Population
Among 814 study children alive at the end of the initial trial 
period (8 weeks of age), 5 had died and 196 were >13 months at 
the time of the CSS survey. Among the remaining 613 children, 
465 (76.0%) were enrolled in this study and NPSs were collected 
from 461 of them (99.1%). Demographic characteristics were 
similar between children included in the CSS and those who 
were not (Table 1). Baseline characteristics (sex, ethnic group, 
season at birth, maternal age, and age at follow-up) in the azi-
thromycin (n  =  226) and the placebo groups (n  =  235) were 
similar, except for a higher number of multiple pregnancies in 
the placebo arm (P = .037; Table 2).
Prevalence of Bacterial Carriage
The prevalence of S. pneumoniae carriage was high and similar 
between arms (85.0% vs 82.1% in the azithromycin and placebo 
arms, respectively; odds ratio [OR],  1.23 [95% CI, .73–2.08]; 
Table 3). The prevalence of S. aureus carriage was lower but also 
similar between arms (21.7% vs 21.3% in the azithromycin and 
placebo arms respectively; OR, 1.02 [95% CI, .64–1.64]).
Prevalence of Antibiotic Resistance
Streptococcus pneumoniae
Only 6 of the 385 S. pneumoniae isolates were resistant to azith-
romycin, and prevalence was similar between study arms (1.8% 
vs 0.9% in the azithromycin and placebo arms, respectively; 
OR,  2.10 [95% CI, .30–23.38]). Prevalence of S.  pneumoniae 
resistance against the other antibiotics tested was also similar 
between arms (Table 4). D-test was performed on 14 samples (6 
azithromycin and 8 erythromycin resistant) and all were nega-
tive. Resistance to cotrimoxazole based on disk diffusion was 
the highest among all the antibiotics tested (Table 4). Among 
the cotrimoxazole-resistant isolates, 30% were retested using 
Etest and 63.3% (57 of 90) were confirmed. All S. pneumoniae 
isolates were susceptible to at least 3 of the antibiotics tested, 
Table 1. Comparison of Children in the 12-Month Survey With Those Who 
Did Not Participate
Variable 12-Month Survey, no./No. (%) P Value
Included Not Included
Sex
 Female 230/465 (49.5) 175/378 (46.3) .360
 Male 235/465 (50.5) 203/378 (53.7)
Ethnicity
 Mandinka 201/462 (43.5) 151/361 (41.8) .367
 Wollof 49/462 (10.6) 45/361 (12.5)
 Jola 80/462 (17.3) 47/361 (13.0)
 Fula 76/462 (16.5) 68/361 (18.8)
 Other 56/462 (12.1) 50/361 (13.9)
Maternal age at delivery, y
 18–19 30/465 (6.5) 37/378 (9.8) .109
 20–29 295/465 (63.4) 244/378 (64.6)
 ≥30 140/465 (30.1) 97/378 (25.7)
Multiple pregnancies
 No 453/465 (97.4) 362/372 (95.8) .183
 Yes 12/465 (2.6) 16/378 (4.2)
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except for 1 isolate in the azithromycin arm that was susceptible 
to only 2 antibiotics (Figure 1).
Staphylococcus aureus
Overall, 13 of the 99 S. aureus isolates were resistant to azithro-
mycin, and prevalence was similar between study arms (3.1% 
vs 2.6% in the azithromycin and placebo arms, respectively; 
OR,  1.22 [95% CI, .35–4.47]). Prevalence of S.  aureus resis-
tance against the other antibiotics was low (<3.0%) and similar 
between arms (Table 4). All S. aureus isolates from both arms 
were susceptible to at least 1 of the antibiotics tested (Figure 2).
Association of Azithromycin Resistance up to 28 Days and 1 Year 
Posttreatment (CSS)
There were 427 participants with complete information on 
S. pneumoniae and S. aureus resistance (samples at the 5 time 
points during the neonatal period and at 1 year posttreatment). 
For S.  pneumoniae, 0.73% of the participants not carrying 
a resistance strain during the neonatal period had a resistant 
strain 1 year after birth; prevalence of resistant strains was sig-
nificantly higher (14.3%) in those carrying a resistant strain 
during the neonatal period (P < .001). For S. aureus, prevalence 
of resistant strains at 1  year was not associated with carriage 
during the neonatal period (2.6% vs 3.9%; P = .524).
DISCUSSION
Twelve months after administering azithromycin to women in 
labor, the prevalence of S. aureus azithromycin resistance pre-
viously observed during the neonatal period had returned to 
baseline levels, with no differences between study arms. This 
was also true for S. pneumoniae azithromycin resistance.
Table 3. Univariate Analysis of Bacterial Carriage by Arm After 12 Months
Bacteria Azithromycin (n = 226), No. (%) Placebo (n = 235), No. (%) OR (95% CI) P Value
Streptococcus pneumoniae
 Yes 192 (85.0) 193 (82.1) 1.23 (.73–2.08) .413
 No 34 (15.0) 42 (17.9)
Staphylococcus aureus
 Yes 49 (21.7) 50 (21.3) 1.02 (.64–1.64) .916
  No 177 (78.3) 185 (78.7)
Abbreviations: CI, confidence interval; OR, odds ratio.
Table 2. Baseline Characteristics of Mothers and Children in the 2 Groups
Characteristic
Azithromycin Group 
(n = 226)
Placebo Group 
(n = 235) P Value
Maternal age at delivery, mean (SD) 26.5 (5.3)a 26.6 (5.0) .684
Mode of delivery
 Vaginal 220 (97.4) 233 (99.2) .165
 Cesarean 6 (2.7) 2 (0.9)
Information at birth
 Multiple pregnancy 2 (0.9) 10 (4.3) .037
 Sexb
  Female 117 (51.8) 104 (44.3) .266
  Male 107 (47.4) 124 (52.8)
Ethnicityc
 Mandinka 93 (41.2) 106 (45.1) .490
 Jola 44 (19.5) 36 (15.3)
 Wollof 26 (11.5) 23 (9.8)
 Fula 37 (16.4) 38 (16.2)
 Others 24 (10.6) 31 (13.2)
Season
 Dry 178 (78.8) 188 (80.0) .909
 Wet 48 (21.2) 47 (20.0)
Child age at follow-up visit, mean (SD) 12.24 (0.6) 12.27 (0.6) .486
Data are presented as No. (%) unless otherwise indicated.
Abbreviation: SD, standard deviation.
aThree missing data in the azithromycin arm.
bNine missing data (2 in the azithromycin arm and 7 in the placebo arm).
cThree missing data (2 in the azithromycin arm and 1 in the placebo arm).
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Prevalence of azithromycin-resistant pneumococcal carriage 
was low among infants from both groups. This was expected as 
prevalence of resistance was low and similar between trial arms 
during the 4 weeks following the intervention [20]. Our results 
are similar to those of the Gambian trachoma trial in which chil-
dren received an annual dose of azithromycin for 1 or 3 years [9] 
and prevalence of S. pneumoniae azithromycin resistance was 
similar between arms 6 months after dose 3. They are also con-
sistent with the trial conducted in northern Tanzania, where no 
association of prevalence of macrolide-resistant S. pneumoniae 
was found 6  months following MDA-Z [25]. Nevertheless, in 
some studies azithromycin resistance persists after MDA-Z. In 
Table 4. Prevalence of Antibiotic-Resistant Bacteria, by Arm, After 12 Months
Bacteria and Antibiotic Azithromycin (n = 226), No. (%) Placebo (n = 235), No. (%) OR (95% CI) P Value
Streptococcus pneumoniae
 AzithromycinR Yes  4 (1.8) 2 (0.9) 2.10 (.30–23.38) .384
No 222 (98.2) 233 (99.1)
 ErythromycinR Yes 5 (2.2) 3 (1.3) 1.75 (.34–11.38) .442
No 221 (97.8) 232 (98.7)
 ChloramphenicolR Yes 8 (3.5) 3 (1.3) 2.84 (.67–16.78) .111
No 218 (96.5) 232 (98.7)
 PenicillinR Yes 0 (0.0) 0 (0.0) NA
No 226 (100.0) 235 (100.0)
 ClindamycinR Yes 1 (0.4) 0 (0.0) NA .307
No 225 (99.6) 235 (100.0)
 CotrimoxazoleR,a Yes 140 (92.1) 152 (93.3) 0.84 (.33–2.17) .696
No 12 (7.9) 11 (6.8)
Staphylococcus aureus
 AzithromycinR,b Yes 7 (3.1) 6 (2.6) 1.22 (.35–4.47) .724
No 219 (96.9) 229 (97.5)
 ErythromycinR,b Yes 5 (2.2) 5 (2.1) 1.04 (.24–4.59) .950
No 221 (97.8) 230 (97.9)
 CefoxitinR Yes 0 (0.0) 2 (0.9) NA (.00–1.99) .165
No 226 (100.0) 233 (99.2)
 ChloramphenicolR Yes 1 (0.4) 3 (1.3) 0.34 (.01–4.32) .334
No 225 (99.6) 232 (98.7)
 ClindamycinR Yes 6 (2.6) 7 (3.0) 0.89 (.24–3.14) .834
No 220 (97.4) 228 (97.0)
Testing was done with Etest and VITEK-2. 
Abbreviations: CI, confidence interval; NA, not applicable; OR, odds ratio; R, resistant.
aOnly 63.3% (57/90) of cotrimoxazole-resistant S. pneumoniae isolates by disk diffusion were confirmed by Etest.
bIsolates of intermediate azithromycin (4 µg/mL) or erythromycin (1–4 µg/mL) resistance were considered sensitive.
Resistant
Sensive 
Resistant by disc diffusion
not confirmed by Etest 
Figure 1. Heat map showing pattern of Streptococcus pneumoniae isolates resistant (R) to at least 1 antibiotic (except cotrimoxazole), by arm. Resistance Etest cutoff 
values: azithromycin, ≥2 μg/mL; penicillin, ≥8 μg/mL; chloramphenicol, ≥8 μg/mL; erythromycin, ≥1 μg/mL; and clindamycin, ≥1 μg/mL. *Cotrimoxazole susceptibility patterns 
for isolates resistant to at least 1 of azithromycin, penicillin, chloramphenicol, erythromycin, and clindamycin are included in the table. Resistance cutoff value was ≤18 mm 
using disk diffusion.
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Ethiopia, prevalence of azithromycin-resistant S.  pneumoniae 
increased after 4 rounds of MDA-Z for trachoma control and 
did not return to baseline 12 months after the last round [14]. 
This is probably due to the higher prevalence of resistance at 
baseline (9.2%) [14] as compared to The Gambia (1.4%) [20] 
and Tanzania (0%) [25], and to the larger number of MDA-Z 
rounds. Indeed, frequent exposure to treatment and higher 
resistance at baseline are associated with increased prevalence 
of macrolide resistance that persists for a very long time [26].
Only 1 isolate (from the azithromycin arm) showed resis-
tance to both macrolides and clindamycin, suggesting consti-
tutive resistance. All clindamycin-sensitive, macrolide-resistant 
isolates had a negative D-test, indicating no evidence of induc-
ible resistance. Macrolide exposure could potentially induce 
clindamycin resistance through methylation of the common 
ribosomal binding site for macrolides, clindamycin as well as 
streptogramin B (MLSB), often referred to as the MLSB pheno-
type [27]. However, in our study population, macrolide expo-
sure did not induce resistance to clindamycin.
For cotrimoxazole, two-thirds of the S. pneumoniae isolates 
resistant by disk diffusion were confirmed by Etest and, there-
fore, actual resistance was probably around 60%. Such high 
prevalence among the children has been previously described 
[28] and is probably the result of high cotrimoxazole use in The 
Gambia; no increase as a result of the intervention was observed.
Nearly all S.  aureus isolates resistant to azithromycin were 
resistant to erythromycin and approximately two-thirds were 
also resistant to clindamycin, suggesting that the underlying 
mechanism was constitutive, mediated by the erm gene [27]. 
There were 2 cases of methicillin-resistant S. aureus (MRSA) in 
the study, both in children from the placebo arm, and therefore 
not associated with the intervention. To our knowledge, this is the 
first time MRSA has been reported from carriage in The Gambia, 
although it was previously reported from invasive isolates [29].
This study had some limitations. One is the lack of informa-
tion between the last sample collection in the main trial and 
the survey done at the infants’ first birthday. We were unable 
to determine how long S.  aureus–resistant isolates persisted. 
Such information is important to determine the potential risk 
of resistance transmission and establishment within the pop-
ulation. Despite the lack of information on antibiotic use by 
the study participants between 2 and 12 months of age, we did 
not expect major differences between trial arms, as this was a 
randomized trial. The survey carried out at about 12  months 
postintervention was able to include about two-thirds of study 
participants, which is a substantial proportion of the study pop-
ulation; we did not observe significant differences between chil-
dren included in the survey and those left out. Exposure to a 
macrolide in our study population may have also resulted in the 
emergence of macrolide-resistant, gram-negative bacteria. In 
Tanzania, rectal swabs collected from young children following 
MDA-Z exposure were significantly associated with higher azi-
thromycin-resistant Escherichia coli carriage at 1 month post-
MDA (OR, 15.27; P  <  .001) and all subsequent surveys [30]. 
Our analysis was based on gram-positive bacteria as we only 
collected NPS.
In conclusion, administering 2 g of azithromycin to Gambian 
women in labor induced a transient azithromycin resistance 
in S.  aureus that lasted <12  months. Although the long-term 
impact on prevalence of resistance of the 2 bacteria is reassur-
ing, pathogenicity and transmissibility of resistant S.  aureus 
strains observed in the short term warrant further investigation.
Resistant
Intermediate
Sensive 
Figure 2. Heat map showing pattern of Staphylococcus aureus isolates resistant (R) to at least 1 antibiotic, by arm. Resistance Etest cutoff values: azithromycin, ≥8 μg/
mL; chloramphenicol, ≥32 μg/mL; erythromycin, ≥16 μg/mL; clindamycin, ≥4 μg/mL; cefoxitin for methicillin-resistant Staphylococcus aureus (MRSA), ≥8. Intermediate Etest 
cutoff values: azithromycin, 4 μg/mL; erythromycin, 1–4 μg/mL.
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